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Background/aim: Smoking is the leading preventable cause of death in the world. There is growing evidence of the need for communitybased programs on smoking cessation. The main purpose of this study is to establish the rate of smoking cessation and restarting in 1
year at the Balçova Smoking Cessation Center.
Materials and methods: This is a prospective study with a study group of 359 individuals who quit smoking at the Balçova Smoking
Cessation Center for at least 4 weeks between October 2009 and April 2010. The outcomes of the study were 1-year cessation rate and
relapse rate. Individuals who reported restarting and/or had CO measurements above 6 ppm were accepted as quitters who had relapsed.
Results: The 1-year rate of smoking cessation was 30.1% for the study group. Of the subjects who quit smoking, 50.1% started smoking
again during the 1-year follow-up. Relapse rate was also higher in nicotine addicts. Pharmacological treatment was associated with
increased success rates in smoking cessation.
Conclusion: Nicotine dependency was shown to be associated with lower rates of smoking cessation and higher rates of relapse.
Therefore, it is important to begin smoking cessation attempts before individuals become serious addicts.
Key words: Smoking cessation, relapse rate, pharmacological treatment

1. Introduction
Smoking is a factor in 6 out of 8 frequent causes of death
globally. Each year, 5 million deaths occur globally due to
tobacco use. This figure is expected to be over 8 million
by the year 2030 (1). In Turkey, 31.2% of people aged 15
or above smoke on a daily basis. The smoking rate among
men (47.9%) is higher than among women (15.2%) (2).
Problems caused by tobacco use were regarded as a major
public health problem in the World Health Organization
Framework Convention on Tobacco Control (3).
For effective tobacco control, local, cultural, social,
economic, political, and legal issues should be taken into
consideration (3). One of the components of MPOWER,
the World Health Organization’s policy package to reduce
global tobacco usage, is to offer assistance to quit tobacco
use (4). The most effective and feasible tool for treatment of
nicotine dependency is suggested to be smoking cessation
centers. Close follow-up and motivation in a specialized
smoking cessation center is reported to increase the success
* Correspondence: ozlempekel@yahoo.com

of quitting smoking (5). While cessation of smoking is
3%–5% without any help from a special center, a specialized
center increases this rate up to 40% (6). Restarting smoking
following a successful cessation within 6–12 months was
reported to be 70%–80% (7). This study aimed to determine
the factors that affect the cessation and restarting of smoking
according to the level of nicotine dependency.
2. Materials and methods
In this prospective study the target population consisted
of 1390 smokers from the “Heart of Balçova” project,
which started in 2007, who had an intermediate or high
Framingham risk score (8). These people were invited to
the smoking cessation center. From those who were invited,
306 smokers (22% of the target population) and another
440 smokers from outside of the target population, making
a total of 746 smokers, were admitted to the center by April
2010. The study group consisted of 581 participants who
were admitted to the center and interviewed at least twice.
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The group that would be followed was defined as the
359 people who did not smoke for 4 weeks starting from
31 May 2010. Sample size was calculated by using Epi
Info 3.4.3 StatCalc with an input of 50% risk of relapse,
with a 5% precision and 95% confidence level, and it was
found to be 186. Admittance to the center was more than
expected and all patients who met the inclusion criteria
were enrolled in the study. Data collection began following
the written approval of the Dokuz Eylül University Ethics
Committee in May 2010 and ended in May 2011.
A 30-min interview was conducted on the first visit
of everyone who was admitted to the smoking cessation
center. Following the interview, behavioral counseling
methods were applied. The second visit was planned for
1 week later and, if the nicotine withdrawal symptoms
were severe, beginning with the people with a high level of
dependency, pharmacotherapy was started. Medications
were given weekly. Visits were weekly for the first
month, every other week for the second month, and then
monthly afterwards. Data were collected with face-toface interviews. Every third month patients had their CO
levels measured at the center. In order to prevent relapse,
behavioral counseling was continued during the visits.
When a patient did not show up for the planned visit he or
she was called and given counseling over the phone lasting
no more than 10 min.
At the end of the 12-month follow-up period, a
statement by the patient or a CO value below 6 ppm was
considered to demonstrate successful cessation of smoking
(9). Relapse was defined as smoking at least 1 cigarette for 7
consecutive days (10). A statement by the patient and/or a
CO value above 6 ppm was considered as relapse. Nicotine
dependency was revealed by the Fagerström dependency
test (11). Pharmacological therapy use was considered as
at least 4 weeks of regular use of the medication. A patient
was considered as lost to follow-up when he or she could
not be reached 4 times on 4 different days.
2.1. Statistical analysis
The associations between dependent and independent
variables were analyzed using the t-test and chi-square
tests. For Cox regression analysis, the time variable in the

model was the duration of follow-up. Restarting smoking
during the 1-year follow-up was analyzed by using Kaplan–
Meier survival analysis and differences between groups
was analyzed by log-rank test. The statistical analysis was
performed using SPSS 15.0 and Epi Info 2002 StatCalc
software (12).
3. Results
People with at least 2 follow-up visits to the smoking
cessation center were included in the analysis. The total
number of participants was 581. The smoking cessation
status of the study group at the end of the 1-year followup is shown in Table 1. By the end of the 1-year follow-up
period, the smoking cessation rate was 30.1%.
Of the 359 patients who did not smoke for at least
4 weeks, 184 (51.3%) began smoking again. The mean
duration of quitting was 125.7 ± 82.0 days.
There was no significant difference between women and
men in relapse. The relapse rate was significantly higher in
the age group of 18–54 years compared to the group over
55. The rate of relapse was higher for employed individuals
compared to unemployed individuals. Education level
and marital status had no significant effect on restarting
smoking.
There were no significant differences in relapse rate
between women and men in survival analysis (P = 0.18)
(log-rank (Mantel–Cox)). Duration without smoking was
8.3 ± 0.3 months in men and 7.8 ± 0.3 months in women.
While the relapse rate was 61.2% for the age group of
18–54 years, it was 41.4% for the group over 55 (log-rank
= 17.5, SD = 1, P = 0.001). The average duration of not
smoking was 7.0 ± 0.3 months for the age group of 18–54
years, while it was 9.1 ± 0.3 months for the group over 55,
which indicates a statistically significant difference. There
was a significant association between dependency level
and restarting smoking. In the univariate analysis, patients
with a high level of dependency were more likely to restart
smoking than those with a lower level of dependency (P <
0.001).When a survival analysis was performed according
to dependency level, it was seen that the group with the
shortest span of cessation consisted of those with a high

Table 1. Distribution of patients in respect to smoking cessation status.
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Status of smoking cessation

Number

Percent

Quit, successful

175

30.1

Quit, relapsed

184

31.7

Quit, lost to follow-up

7

1.2

Never quit

215

37.0

Total

581

100.0
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level of dependency (log-rank = 19.75, SD = 4, P = 0.001).
When the treatment methods used by the research group
were compared, the relapse risk for those who were treated
with pharmacotherapy was significantly lower than for those
who received behavioral treatment (P < 0.05). The relapse
rate in the group that took varenicline was significantly
lower than among those who received behavioral treatment.
The relapse rate in the group that took bupropion was not
statistically different compared to those who were only
treated behaviorally. There was no significant association
between receiving nicotine replacement treatment and
restarting smoking. The status of restarting smoking for
each therapy group is given in Table 2.
When survival analysis was performed a significant
difference was detected between treatment methods
employed (log-rank = 25.4, SD = 3, P = 0.0001). The
duration for permanence in smoking cessation was highest
in the group that used varenicline. In the univariate
analysis, patients with a high level of dependency were
more likely to restart smoking than those with a lower
level of dependency (P < 0.001). When survival analysis
was performed according to dependency level, it was seen
that the group with the shortest span of cessation consisted
of those with a high level of dependency (Figure) (log-rank
= 19.75, SD = 4, P = 0.001).
Table 3 shows the Cox regression analysis results
regarding the status of restarting smoking according to
nicotine dependency level in the research group. Four
different models were employed for these analyses. The
first model included nicotine dependency level, age, and
sex, while the second model added employment, the third
model added smoking in the household, and the fourth
model added the use of medicine.
The risk of restarting smoking for the group with a high
level of nicotine dependency was 2.10 (95% CI = 1.48–2.97)
compared to the group with a lower dependency level.

With adjustments in Model 1 according to age and sex,
the hazard ratio (HR) decreased but retained its statistical
significance (HR = 1.89, 95% CI = 1.32–2.69). In Model 2,
which covered employment as well as age and sex, the HR
for relapse in the group with higher dependency decreased
compared to the group with lower dependency and, again,
it retained its statistical significance (HR = 1.84, 95% CI =
1.28–2.63). In Model 3, which was adjusted for age, sex,
employment, and smoking in the household, the statistical
significance was maintained although the HR decreased
(HR = 1.83, 95% CI = 1.28–2.63). Model 4 added the use
of medicine, and the HR for relapse of the group with
higher dependency increased compared to the group with
lower dependency and it was statistically significant (HR =
1.89, 95% CI = 1.32–2.72). In summary, the relapse risk for
those with higher nicotine dependency was almost 2 times
higher than that for those with lower dependency even
when variables such as age, sex, employment, smoking in
the household, and use of medication were controlled.
4. Discussion
In the research group, the smoking cessation rate for 1
year was 30.1%. Three hundred and fifty-nine people
who did not smoke for at least 4 weeks were followed for
1 year, and 51.3% of these people restarted smoking. In
a 3-year observation study conducted in Trabzon, Turkey,
the smoking cessation rate was detected to be 47.8% (13).
The smoking cessation rate in this research group over
1 year is lower than the rate in Trabzon. This difference
may arise from the fact that the study conducted in
Trabzon was based on a center established in a university
hospital; people who wished to quit smoking and had high
awareness of their health status consulted that center in
person and they had higher educational levels, which may
be another indicator of higher awareness. In addition, in
the Kaplan–Meier survival analysis comparing sex, no

Table 2. The effect of treatment method on restarting smoking.
Restarted smoking status
Treatment method

Restarted

Did not restart

Number

%*

Number

%*

P

Behavioral treatment
Pharmacologıcal treatment

119
65

55.9
44.5

94
81

44.1
55.5

0.03**

Type of therapy
Bupropion
Varenicline
Nicotine replacement therapy

43
8
14

64.2
17.0
43.8

24
39
18

35.8
83.0
56.3

0.23
0.0001
0.19

*Row percentage, chi-square test.
**Pharmacotherapy was compared to behavioral treatment.
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1.0

Nicotine
dependency
level

Continuing cessation

0.8

1.00
2.00
3.00
4.00
5.00
1.00-censored
2.00-censored
3.00-censored
4.00-censored
5.00-censored

0.6

0.4

0.2

0.0
0.00

2.00

4.00
6.00
8.00
Smoking cessation

10.00

12.00

Figure. Rates of smoking cessation according to months and nicotine dependency
levels.

significant difference was found in terms of permanence
in smoking cessation, which is similar to this study.
In 3 studies carried out at pulmonology clinics, success
rates for 1 year were detected to be 41.2%, 45.5%, and
40% respectively (14–16). The reason for higher rates of
smoking cessation compared to this study may be due to
the fact that people who consulted the pulmonology clinics
mainly had complaints about smoking and a high risk of
disease. It may be thought that individuals with risks have
a higher motivation to quit smoking.
In a community-based intervention trial study
conducted in Canada, the smoking cessation rate for 1 year
was detected to be 43% (17). The reason for a higher rate
of smoking cessation may be due to the fact that the social
support intervention administered to those who wished
to quit smoking covered the family of the individuals as
well. Additionally, more extensive efforts were spent to
increase social awareness, which may be another factor in
increasing the success.
In a study conducted in the United States, the rate of
restarting smoking at the end of 6 months was detected
to be 62.9%. Furthermore, in the Kaplan–Meier survival
analysis based on sex, no significant difference was
determined in smoking cessation permanence, which is
parallel to the finding obtained in this study. Japuntich et
al. reported the rate of restarting smoking at the end of
6 months to be 62.9% (10). Additionally, the same study
revealed that rate of restarting smoking in women and
people with a high nicotine dependency was significantly
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higher. The reason for a higher rate of restarting smoking
compared to our study may be due to a shorter period of
observation. In an International Tobacco Control study
covering a 3-year observation of nicotine replacement
treatment, the rate for restarting smoking was detected
to be 37% (18). No significant relationship was found
between restarting and sex, which is parallel to this study.
In addition, the restart rate in people who were over
55 was significantly lower. The difference in restarting
smoking may be due to a longer period of observation and
the relapse rate, which, as was expected, decreased in the
course of time.
According to dual analysis and survival analysis in
the research group, the restart rate in the employed group
was significantly higher compared to those who were
unemployed. In a study conducted in England, where
observations lasted for 13 years, the restart rate for people
who were unemployed was significantly higher (19).
The average age of participants in the research group of
the study conducted in England was lower. Thus, while
the working group was younger in the present study,
the unemployed group was younger in the study from
England. The difference may be due to age rather than
employment. It is also possible that the smoking ban is not
applied properly in small offices in Turkey, and smokers
encourage one another to smoke.
In this study, no significant relationship was found
between a smoking environment and restarting. In the
Inter99 study, which was a community-based intervention
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Table 3. The relationship between nicotine dependency level and status of restarting
smoking in Cox regression models.
RR

CI (95%)

P

Low**

1

-

0.001

Moderate

1.48

0.92–2.36

0.09

High

2.10

1.48–2.97

0.001

Low**

1

-

0.002

Moderate

1.37

0.85–2.19

0.18

High

1.89

1.32–2.69

0.001

Low**

1

-

0.003

Moderate

1.36

0.85–2.18

0.19

High

1.84

1.28–2.63

0.001

Low**

1

-

0.003

Moderate

1.36

0.85–2.18

0.19

High

1.83

1.28–2.63

0.001

Nicotine* dependency level

Model 1***
Nicotine dependency level

Model 2****
Nicotine dependency level

Model 3*****
Nicotine dependency level

Model 4******
Nicotine dependency level
Low**

1

Moderate

1.38

0.86–2.21

0.002
0.18

High

1.89

1.32–2.72

0.001

*Cox regression analysis of relapse/nicotine dependency level, which was not modified
according to any of the variables.
**Taken as reference.
***Model 1: Age was modified according to sex.
****Model 2: Age was modified according to sex and employment.
*****Model 3: Age was modified according to sex, employment, and smoking in
household.
****** Model 4: Age was modified according to sex, employment, smoking in household,
and use of medicine.

trial study, no significant effect of a smoking environment
was found when it was controlled according to work (20).
However, it was seen that the group with a lower level
of education had a 1.82 times greater risk of restarting
smoking if they were in a smoking environment (95% CI
= 1.4–2.4).
In the present study, the restart rate was significantly
higher among those with a higher level of nicotine
dependency. In a study conducted in England (21), no
significant relationship was detected between restart rate

and nicotine dependency level at the end of 3 months.
These different results may stem from shorter period of
observation. In Bolt and Piper’s study, nicotine dependency
level was compared via a different scale and patients were
either treated with bupropion or a nicotine replacement.
At the end of 6 months, patients with lower dependency
levels had significantly less relapse than those with a higher
dependency level (22). Another study compared bupropion
with a placebo in terms of restarting. At the end of 12
months, the restart rate was significantly lower among those
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with lower dependency levels, which was a finding similar
to the present study (23). In our group the restart rate was
significantly lower among patients who were treated with
pharmacotherapy than among the patients who received
behavioral treatment at the end of 1 year. The Cox regression
analysis detected that permanence in smoking cessation
was highest in the group who took varenicline. In a doubleblind randomized control study varenicline was used for 12
weeks. At the end of 1 year of observation, it was seen that
varenicline was 1.34 times significantly more efficient than
a placebo in preventing restarting (95% CI = 1.06–1.69)
(24). In a systematic review, behavioral treatment supported
by telephone calls resulted in no significant effect in terms
of preventing relapse. The same study showed that the effect
of a nicotine band to prevent restarting in long periods of
observations was 1.30 times higher (95% CI = 1.06–1.61)
and the effect of bupropion was 1.25 times higher (95%
CI = 0.86–1.81); however, neither was significant (25).
In a previous metaanalysis, it was seen that behavioral
treatments that were implemented in various frequencies
to prevent restarting had no significant effect. The same
metaanalysis also showed that there was no significant
effect of bupropion or nicotine replacement treatments
on preventing relapses. However, varenicline decreased
the rate of relapse at a significant level (RR: 1.18, 95% CI =
1.03–1.36) (26).
This study was planned as an intervention trial study
of the Heart of Balçova Project regarding people who had
a smoking habit and had a moderate or higher risk for
coronary heart diseases. It was different from other cessation
studies in that most of the participants were invited by
community volunteers based on their risk status, instead of
their applying themselves. Additionally, it was not located
in a health facility, like a primary care unit or a hospital.
Compliance to treatment might have decreased since it was
not perceived as a health organization by the participants.
Starting packets for treatments used in the study were
distributed by the center free of charge. Attendance packets
were not used in general, although they were written for
prescriptions. Pharmacotherapy was not continued free of
charge for the full course; therefore, the effect of treatment
should be evaluated with caution. Providing free medicine
is one of the strengths of the study, although it also caused

patients who had not truly decided to quit smoking to
participate in the study. This may have given rise to lower
cessation and higher relapse rates.
Cessation and relapse rates for 12 months obtained
through this study are in compliance with the intervals in
the literature. There are only a limited number of studies in
Turkey about relapse in smoking cessation. Therefore, the
observation of not only cessation but also restarting is the
strongest aspect of the study.
The study succeeded in revealing elements regarding
cessation and restart because it was a prospective study
and there were only a few lost cases during follow-up.
Performing the necessary measurements, in addition to
self-reporting in order to learn smoking cessation status,
increased the validity of the study.
In conclusion, this study revealed that the smoking
cessation rate for 1 year was 30.1% and the relapse rate was
51.3%. As nicotine dependency level increased, smoking
cessation rate decreased significantly and the relapse rate
increased significantly.
Among the pharmacotherapy groups, only patients
who took varenicline had a significantly lower level
of restarting compared to those who did not use any
medicine. This result should be interpreted carefully since
the study was not a randomized trial with a control group.
Attempts to quit smoking should address the whole
population, and authorities should be aware of the aspect
of observation. Since the employed have higher rates
of relapse, attempts to include office workers should be
increased. In order to increase the rate of cessation and
provide permanent cessation, people with a high nicotine
dependency should be given priority in pharmacotherapy
initially. Individuals appropriate for pharmacotherapy
should be screened systematically, and the expense of
treatment should be covered by the general insurance
system. These efforts will result in decreased morbidity and
mortality due to smoking and a beneficial contribution to
public health.
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